How To Compare Quality of Life of Breast Cancer Patients in Clinical Trials

  • R. D. Gelber
  • B. F. Cole
  • A. Goldhirsch
  • for the International Breast Cancer Study Group, Bern, Switzerland
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 127)


Quality of life of breast cancer patients receiving systemic therapy has been studied in advanced disease when treatments are given with palliative intent [1–3]. In the adjuvant setting, however, therapies associated with acute toxic effects are administered during a time when patients are free of disease-related symptoms [4]. The expectation is that the investment of this period of toxicity will be balanced by a delay in relapse and improvement in survival for the future. The toxic effects are felt by the entire population of patients, while it is possible that the benefits of treatment might be enjoyed by only some.


Breast Cancer Breast Cancer Patient Postmenopausal Patient Premenopausal Patient Utility Coefficient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brunner KW, Sonntag RW, Martz G et al. (1975) Controlled study in the use of combined drug therapy for metastatic breast cancer. Cancer 36:1208–1219PubMedCrossRefGoogle Scholar
  2. 2.
    Priestman TJ, Baum M (1976) Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet i:899–901CrossRefGoogle Scholar
  3. 3.
    Coates AS, Gebski V, Bishop JF et al., for the Australian New Zealand Breast Cancer Trials Group (1987) Improving quality of life during chemotherapy for advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490–1495PubMedCrossRefGoogle Scholar
  4. 4.
    Coates AS, Glasziou P, McNeil D (1990) On the receiving end. III. Measurement of quality of life during cancer chemotherapy. Ann Oncol 1:213–217PubMedGoogle Scholar
  5. 5.
    Marrow GR, Black PM, Dudgeon DJ (1991) Advances in data assessment: application to the etiology of nausea reported during chemotherapy, concerns about significance testing, and opportunities in clinical trials. Cancer 67:780–787CrossRefGoogle Scholar
  6. 6.
    Schumacher M, Olschewski M, Schulgen G (1991) Assessment of quality of life in clinical trials. Stat Med 10:1915–1930PubMedCrossRefGoogle Scholar
  7. 7.
    Gelber RD, Goldhirsch A (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772–1779PubMedGoogle Scholar
  8. 8.
    Gelber RD, Gelman RS, Goldhirsch A (1989) A quality-of-life-oriented endpoint for comparing therapies. Biometrics 45:781–795PubMedCrossRefGoogle Scholar
  9. 9.
    Goldhirsch A, Gelber RD, Simes RJ et al., for the Ludwig Breast Cancer Study Group (1989) Costs and benefits of adjuvant therapy in breast cancer: a quality- adjusted survival analysis. J Clin Oncol 7:36–44PubMedGoogle Scholar
  10. 10.
    Glasziou PP, Simes RJ, Gelber RD (1990) Quality adjusted survival analysis. Stat Med 9:1259–1276PubMedCrossRefGoogle Scholar
  11. 11.
    Gelber RD, Goldhirsch A, Cavalli F, for the International Breast Cancer Study Group (1991) Quality-of-life-adjusted evaluation of a randomized trial comparing adjuvant therapies for operable breast cancer. Ann Intern Med 114:621–628PubMedGoogle Scholar
  12. 12.
    Gelber RD, Goldhirsch A, Hürny C, Bernhard J, Simes RJ, for the International Breast Cancer Study Group (1992) Quality of life in clinical trials of adjuvant therapies. Natl Cancer Inst Monogr 11:127–135Google Scholar
  13. 13.
    Ludwig Breast Cancer Study Group (1988) Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med 319:677–683CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • R. D. Gelber
    • 1
    • 2
  • B. F. Cole
    • 2
  • A. Goldhirsch
    • 3
  • for the International Breast Cancer Study Group, Bern, Switzerland
  1. 1.Harvard Medical School and Harvard School of Public HealthBostonUSA
  2. 2.Dana-Farber Cancer InstituteBostonUSA
  3. 3.International Breast Cancer Study GroupOspedale CivicoLuganoSwitzerland

Personalised recommendations